Sugi Predict

Sugi Predict / Compounds / SCHEMBL343580

SCHEMBL343580

SCHEMBL343580

Clc1ncc2cnn(-c3ccccc3)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.56
▸ ALDH1A1 P00352 7/20 0.44
▸ HSD17B10 Q99714 6/20 0.44
▸ KMT2A Q03164 6/20 0.44
▸ MEN1 O00255 5/20 0.44
▸ TSHR P16473 3/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ EGFR P00533 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ PI4KA P42356 1/20 0.44
▸ PI4K2B Q8TCG2 1/20 0.44
▸ PI4K2A Q9BTU6 1/20 0.44
▸ PI4KB Q9UBF8 1/20 0.44
▸ MAPT P10636 6/20 0.44
▸ HTT P42858 5/20 0.44
▸ NPC1 O15118 5/20 0.44
▸ RAB9A P51151 5/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ MITF O75030 1/20 0.44
▸ S1PR4 O95977 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087457 0.80 EIF2AK4 (0.53) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL1662245 0.79 KDM4E (0.56) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL29387304 0.79 IRAK4 (0.42) KDM4ECYP1A2NPC1RAB9ATP53
SCHEMBL18367194 0.79 IRAK4 (0.42) KDM4ECYP1A2NPC1RAB9ATP53
SCHEMBL31469618 0.77 KDM4E (0.57) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL29390461 0.76 KDM4E (0.51) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL29387290 0.76 KDM4E (0.51) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL18366926 0.76 KDM4E (0.51) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL18366927 0.76 KDM4E (0.51) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL30587478 0.76 PIM1 (0.36) KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630554-B2 Pyrimidinone compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2026-05-19 — — US disclosed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 — — US disclosed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 — — EP disclosed
US-20240002388-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2024-01-04 — — US disclosed
CN-111269221-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2023-09-26 — — CN disclosed
EP-4200281-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-06-28 — — EP disclosed
CN-116249696-A Pyrimidinone compounds and use thereof 和记黄埔医药（上海）有限公司 2023-06-09 — — CN disclosed
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-11-03 — — US disclosed
EP-3317269-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2022-09-21 — — EP disclosed
WO-2022037585-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-02-24 — — WO disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 — — US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 — — US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 — — US disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 — — WO disclosed
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 — — US disclosed
US-8637529-B2 Pyrazolo[3,4-d]pyrimidine compounds AbbYie Inc. (US) 2014-01-28 — — US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 — — US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 — — EP disclosed
US-20120015963-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — US disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015963-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS CHUK, MAP2K2, CDK3 KDM4E 2255/4885ALDH1A1 2600/4885HSD17B10 4619/4885
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 KDM4E 3546/4885ALDH1A1 1195/4885HSD17B10 942/4885
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 KDM4E 621/4885ALDH1A1 2233/4885HSD17B10 4555/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 KDM4E 3546/4885ALDH1A1 1195/4885HSD17B10 942/4885
US-20240002388-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF TYMP, DPYD, DHFR KDM4E 2745/4885ALDH1A1 295/4885HSD17B10 1812/4885
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 KDM4E 3546/4885ALDH1A1 1195/4885HSD17B10 942/4885
US-12630554-B2 Pyrimidinone compounds and uses thereof CYP2D6, TPMT, CYP2B6 KDM4E 3657/4885ALDH1A1 248/4885HSD17B10 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.